Clade I Mpox in US: Cases, Distinctions & Public Health Updates

What is Clade I Mpox and how does it differ from Clade II?

Mpox is caused by the monkeypox virus (MPXV). Scientists divide MPXV into two primary clades — Clade I and Clade II — which are genetically distinct and historically associated with different illness patterns and geographic origins.

Clade I: Historically found in Central and Eastern Africa and previously linked with higher mortality in older data sets. Recent global and U.S. cases have generally been milder when patients receive timely medical care. Clade I includes subclades (Ia and Ib) and has caused ongoing outbreaks in parts of Africa since 2024 (WHO, CDC clinical overview).

Clade II: Historically associated with West Africa. The Clade IIb strain drove the 2022–23 global outbreak and was associated with lower hospitalization and death rates than older Clade I reports.

Symptoms for both clades are similar: fever, swollen lymph nodes, headache, muscle aches, fatigue and a characteristic rash or lesions that can last two to four weeks. Prevention and treatment focus on vaccination (JYNNEOS), early testing, and supportive care (CDC).

U.S. cases and timeline — clarifying reports

Federal and state records show the first confirmed U.S. Clade I Mpox case was reported from California on Nov. 15, 2024. The patient had recent travel to a region with Clade I transmission, tested positive for Clade I MPXV DNA, and recovered without severe complications; no linked secondary cases were immediately identified (CDC HAN advisory).

From late 2024 through February 2026, U.S. health authorities reported a total of 11 confirmed Clade I Mpox cases. Some later cases lacked recent travel, and genomic data indicate limited chains of transmission following travel-associated introductions. Federal case definitions were updated to guide detection and reporting; confirmation requires PCR or sequencing that identifies Clade I MPXV DNA (CDC case definitions).

“Current Clade I activity in the U.S. poses low risk to the general public,” according to federal public-health summaries; targeted prevention for at‑risk groups remains advised (CDC situation summary).

Testing, vaccines and public health guidance

Public health agencies emphasize testing, isolation of confirmed cases, contact tracing, and vaccination for people at higher risk. The JYNNEOS vaccine is approved for prevention of mpox in at-risk adults and is recommended as a two-dose series for optimal protection (CDC vaccine page).

• Who should get tested: People with mpox-consistent symptoms (fever, new rash, swollen lymph nodes) or known exposure to a confirmed case. Travelers from regions with Clade I transmission should inform clinicians of travel history.
• Laboratories and reporting: The CDC requests rapid reporting of suspected Clade I cases; some assays may not distinguish subclades, so sequencing is used for confirmation when needed (CDC case definitions).
• Risk to the public: Federal officials state current detections are not a broad public-health threat but warrant vigilance and targeted prevention in clinical and at‑risk settings (CDC situation summary).

Hantavirus detections in Europe: what health officials are watching

The WHO hantavirus fact sheet notes new hantavirus detections in Spain and France. Hantaviruses are primarily spread through contact with infected rodents or their droppings. Human infections are rare but can cause serious respiratory or renal illnesses depending on the virus type.

European authorities are investigating exposures, virus types involved, and any public risk. Historically, hantavirus cases in Europe are sporadic and localized; public advice centers on rodent control, safe cleanup of droppings, and seeking care for respiratory symptoms after potential exposure (CDC hantavirus information).

Implications for San Diego

Economic impact

Tourism and travel: San Diego’s summer festivals and conventions rely on visitor confidence. Officials say low general risk should not deter travel, but event organizers should provide clear health guidance and vaccine information (CDC vaccine page).

Health system costs: Targeted testing and vaccination for at-risk groups could raise short-term public-health spending; federal and state stockpiles aim to limit local fiscal burdens.

Political consequences & social effects

Local policy and messaging: San Diego County should coordinate clear, nonpartisan messaging aligned with state guidance to prevent confusion and politicization.

Communities at higher risk: Outreach must focus on recent travelers and close contacts of cases to provide testing and vaccination access without stigma.

Schools and workplaces: Remind staff and students about infection-control basics — stay home when ill and seek testing if symptomatic.

Cultural relevance

Event organizers are encouraged to promote vaccination among at‑risk attendees and provide on-site health information so events can continue safely without unnecessary alarm.

Practical applications for residents

• Vaccine access: San Diegans at increased risk or with close contact to confirmed cases should contact San Diego County Public Health or their healthcare provider about JYNNEOS vaccination.
• When to seek care: Anyone with fever and a new rash, particularly with swollen lymph nodes or recent travel, should seek medical evaluation and disclose possible exposure.
• Rodent precautions: To reduce hantavirus risk, avoid contact with wild rodents and droppings, seal homes against rodents, and follow safe cleanup guidance (WHO hantavirus fact sheet, CDC hantavirus information).

Sources and further reading

• CDC HAN Advisory on Clade I Mpox
• CDC clinical overview of mpox
• CDC mpox situation summary
• CDC mpox case definitions
• CDC mpox vaccine information (JYNNEOS)
• WHO mpox fact sheet
• WHO hantavirus fact sheet
• CDC hantavirus information

For the latest local guidance, consult San Diego County Public Health and the California Department of Public Health websites, and follow CDC reporting guidance for clinicians (CDC case definitions).